The British journal of dermatology
-
Randomized Controlled Trial Multicenter Study
Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Etanercept, a soluble tumour necrosis factor receptor, lessens the severity of psoriasis as measured by physician-reported clinical outcomes. Equally important is the patient perspective on the effect of etanercept therapy on daily life. ⋯ Etanercept therapy improves PROs in patients with psoriasis and makes a meaningful difference to their lives. These results support the efficacy profile of physician-reported clinical measures while providing a more complete understanding of the benefits experienced by patients with psoriasis treated with etanercept.